Relevant experimental data showed that metabolic reprogramming of tumour-specific CD8+ T cells may be a strategy to promote their survival in a metabolically unfavourable TME, and they can be thus used to improve the clinical efficacy of immunotherapy (Manzo et al., 2020). This evidence concerns the gene CD8A and neoplasm.